p53siRNA therapy reduces cell proliferation, migration and induces apoptosis in triple negative breast cancer cells
- 763 Downloads
p53 protein is probably the best known tumor suppressor. Earlier reports proved that human breast cancer cells expressing mutant p53 displayed resistance to apoptosis. This study is intended to investigate, the potential applications of RNA interference (RNAi) to block p53 expression, as well as its subsequent effect on cell growth, apoptosis and migration on a triple negative human breast cancer cell line (Hs578T). p53siRNA significantly reduced cell index (CI) compared to the control and we observed an inhibition of cellular migration in the interval of time between 0 and 30 h, as shown in the data obtained by dynamic evaluation using the xCELLigence System. Also, by using PCR-array technology, a panel of 84 key genes involved in apoptosis was investigated. Our studies indicate that the knockdown of p53 expression by siRNA modulates several genes involved in cell death pathways and apoptosis, showing statistically significant gene expression differences for 22 genes, from which 18 were upregulated and 4 were downregulated. The present research also emphasizes the important role of BCL-2 pro-apoptotic family of genes (Bim, Bak, and Bax) in activating apoptosis and reducing cell proliferation by p53siRNA treatment. Death receptors cooperate with BCL-2 pro-apoptotic genes in reducing cell proliferation. The limited success may be due to the activation of the antiapoptotic gene Mcl-1, and it may be associated with the resistance of triple negative breast cancer cells to cancer treatment. Thus, targeting p53siRNA pathways using siRNA may serve as a promising therapeutic strategy for the treatment of breast cancers.
Keywordsp53siRNA Triple negative breast cells Cell proliferation Migration Apoptosis
This study was partially financed by a grant from the Romanian National University Research Council project PD 533/28.07.2010 “Combining chemotherapeutic effects of flavan-3-ols with RNA interference target therapy in cancer” and partially by a POSCCE 709/2010 Grant with title: “Clinical and economical impact of proteome and transcriptome molecular profiling in neoadjuvant therapy of triple negative breast cancer (BREAST IMPACT)”.
Conflict of interest
The authors report no conflicts of interest in this study.
- 12.Rye PD, Stigbrand T (2004) Interfering with cancer: A brief outline of advances in RNA interference in oncology. Tumor Biology 25:5–6Google Scholar
- 15.Ma CX, Cai S, Li S, Ryan CE, Guo Z, Schaiff WT, Lin L, Hoog J, Goiffon RJ, Prat A, Aft RL, Ellis MJ, Piwnica-Worms H (2012) Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor Models. J Clin Invest 122(4):1541–1552PubMedCrossRefGoogle Scholar
- 17.Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi Y, Xiong W, Li G, Lu J, Fodstad O, Riker AI, Tan M (2010) MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 285(28):21496–21507PubMedCrossRefGoogle Scholar
- 24.Booy EP, Henson ES, Gibson SB (2011) Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer. Oncog 30:2367–2378Google Scholar
- 25.Woods NT, Yamaguchi H, Lee FY, Bhalla KN (2007) Wang Anoikis HG. initiated by Mcl-1 degradation and Bim induction, is deregulated during oncogenesis. Cancer Res 67:10744Google Scholar
- 26.Qin W, Hu J, Guo M, Xu J, Li J, Yao G et al (2003) BNIPL-2, a novel homologue of BNIP-2, interacts with Bcl-2 and Cdc42GAP in apoptosis. Biochem Biophys Res Commun 308:379–385Google Scholar
- 27.Debily MA, Marhomy SE, Boulanger V, Eveno E, Mariage-Samson R, Camarca A et al (2009) A functional and regulatory network associated with PIP expression in human breast cancer. PLoS One 4(3):4696Google Scholar
- 28.Lu Y, Chen GQ (2011) Effector caspases and leukemia. Int J of Cell Biol. doi: 10.1155/2011/738301
- 29.Valentín-Acevedo A, Sinquett FL, Covey LR (2011) c-Rel deficiency increases caspase-4 expression and leads to ER stress and necrosis in EBV-transformed cells. PLoS One 6(10):25467Google Scholar
- 30.Smolnikar K, Löffek S, Schulz T, Michna H, Diel P (2000) Treatment with the pure antiestrogen faslodex (ICI 182780) induces tumor necrosis factor receptor 1 (TNFR1) expression in MCF-7 breast cancer cells. Breast Cancer Res Treat 63(3):249–259Google Scholar
- 31.Adams JM, Cory S (2007) The Bcl-2 apoptotic switch in cancer development and therapy Bcl-2 apoptotic switch in cancer. Oncog 26:1324–1337Google Scholar
- 32.Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. PNAS 2(38):13550–13555Google Scholar